2 Healthcare Stocks Under $5 Rated 'Buy' in the POWR Ratings

NYSE: CO | Global Cord Blood Corporation  News, Ratings, and Charts

CO – With the continued spread of the COVID-19 Delta variant in several parts of the world, the healthcare industry continues to command investors’ attention. The industry is also expected to continue growing on the rising demand for treatments for chronic diseases. Thus, we think it could be wise to bet on quality healthcare stocks Global Cord Blood (CO) and So-Young International (SY), which are trading at less than $5 per share. These names are also rated ‘Strong Buy’ or ‘Buy’ in our proprietary POWR Ratings system. Read on.

Governments worldwide have been investing heavily in their healthcare systems to prevent or more effectively combat COVID-19 pandemic-like situations. Rising chronic diseases are also boosting the demand for healthcare solutions. These tailwinds are of import to Investors, whose interest in the healthcare stocks is evidenced by the Health Care Select Sector SPDR Fund’s (XLV) 16.2% year-to-date returns.

As China warns of the further spread of coronavirus, the healthcare industry will likely continue enjoying the market’s attention. Indeed, according to a Business Wire report, the global healthcare market is expected to reach $11.91 trillion by 2022.

So, we think it could be wise to bet on international healthcare stocks Global Cord Blood Corporation (CO) and So-Young International Inc. (SY), which are trading at less than  $5 but possess sound fundamentals. Furthermore, these stocks are rated ‘Strong Buy’ or ‘Buy’ in our proprietary POWR Ratings system.

Click here to checkout our Healthcare Sector Report for 2021

Global Cord Blood Corporation (CO)

Based in Hong Kong, CO and its subsidiaries provide umbilical cord blood storage and ancillary services. The company operates three cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province.

On August 30, 2021, Ting Zheng, CO Chairperson and CEO, said, “We recorded 19,673 new subscribers during the first quarter of fiscal 2022, as China’s approach largely kept COVID-19 under control and consumer concerns gradually alleviated.”

CO’s net revenue increased 12.2% year-over-year to $48.81 million in its fiscal first quarter, ended June 30, 2021. Its gross profit came in at $41.41 million, up 12.6% year-over-year. While its net income increased 3% year-over-year to $21.13 million, its EPS came in at $0.17, up 2.8% year-over-year. Over the past nine months, the stock has gained 8.2% in price to close yesterday’s trading session at $4.37.

CO’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which indicates a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

CO has an A grade for Quality, and a B grade for Value, Stability, and Sentiment. Within the Medical – Diagnostics/Research industry, it is ranked #3 out of 58 stocks. Click here to see the additional POWR Ratings for Growth and Momentum for CO.

So-Young International Inc. (SY)

Headquartered in Beijing, China, SY operates an online platform for medical aesthetics and consumption healthcare services focused on discretionary medical treatments. It has approximately 6,900 medical aesthetic service providers and 4,200 other consumption healthcare service providers.

On June 28, 2021, SY agreed with Wuhan Miracle Laser Systems, Inc. and Wuhan Zeqi Technology Co., Ltd., a shareholder of Wuhan Miracle, to acquire a controlling interest in Wuhan Miracle. Xing Jin, SY’s Chairman and CEO, said, “We hope our strategic investment in Wuhan Miracle will enable us to continue to seize the opportunities of the industry and bring greater returns to our shareholders.”

SY’s revenues increased 37.7% year-over-year to $69.98 million for the second quarter, ended June 30, 2021. Its gross profit increased 41.6% year-over-year to $60.87 million. Also, its net income increased 2,591.3% year-over-year to $8.92 million, while its EPS came in at $0.08, representing a 2,550% year-over-year rise.

For its fiscal year 2021, SY’s revenue and EPS are expected to grow 36.5% and 161.5% year-over-year to $275.24 million and $0.34, respectively. Over the past month, the stock has gained 3.3% to close yesterday’s trading session at $4.38.

SY’s strong fundamentals are reflected in its POWR ratings. The stock has an overall B rating, which equates to a Buy in our proprietary rating system.

In addition, it has an A grade for Value and Sentiment, and a B grade for Growth and Quality. SY is ranked #4 of 86 stocks in the Medical – Services industry. Click here to see the additional POWR Ratings for SY (Stability and Momentum).

Click here to checkout our Healthcare Sector Report for 2021


CO shares were trading at $4.28 per share on Tuesday morning, down $0.09 (-2.06%). Year-to-date, CO has gained 15.36%, versus a 23.55% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
COGet RatingGet RatingGet Rating
SYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

How to Beat the Market the Rest of the Year?

The easy gains that came at the start of this new bull market are fading away fast. In fact the stock market (SPY) has become quite volatile with 2022 starting off with a nasty correction. Gladly there are easy solutions as will be shared in this commentary to get you on the right path to outperform the market the rest of the year. Read the rest below...

:  |  News, Ratings, and Charts

3 Stocks that Are Thriving in an Inflationary Environment

Inflation is one of the biggest threats facing the economy. One profitable strategy during this period of high inflation is to focus on stocks that have pricing power, as these companies’ margins will continue to expand. In contrast, stocks without pricing power are likely to underperform as margin compression erodes EPS. Therefore, investors should consider buying these 3 stocks that are thriving in this inflationary environment: Olin (OLN), Nucor (NUE), and Chemours (CC).

:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

:  |  News, Ratings, and Charts

4 Best Value Stocks to Buy in January

In times of high inflation, value stocks tend to outperform growth stocks and have done so over the past year. Amid the rising inflationary pressure and looming interest rate hikes, fundamentally sound value stocks ArcelorMittal (MT), Covestro (COVTY), KT Corporation (KT), and Nature’s Sunshine (NATR) could be solid bets.

:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

Read More Stories

More Global Cord Blood Corporation (CO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CO News